Article

Practical Management of Adverse Events Associated with Bispecific Antibodies for the Treatment of Multiple Myeloma: A Qualitative Interview Study

2026-04-27

Abstract excerpt

<h4>ABSTRACT</h4> <h4>PURPOSE</h4> Bispecific antibodies (BsAbs) represent a major advancement in the management of relapsed/refractory multiple myeloma (RRMM), offering high response rates even in heavily pretreated patients. However, their use presents operational, safety, and supportive care complexities that require coordinated care teams, and evolving infrastructure. This manuscript summarizes best practice...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 60b1959e-6505-5932-a544-4966b993cf5a
DOI: 10.64898/2026.04.24.26350878

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Practical Management of Adverse Events Associated with Bispecific Antibodies for the Treatment of Multiple Myeloma: A Qualitative Interview StudyDOI 10.64898/2026.04.24.26350878Read

Pattern of Use and Efficacy of Daratumumab-based Therapy in Patients With Multiple Myeloma in a Real-world Setting: a Single Institution ExperienceSemantic proximity Read

Multiple myeloma: patient outcomes in real-world practice.Semantic proximity Read

Challenges, Difficulties, and Delayed Diagnosis of Multiple MyelomaSemantic proximity Read

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal AntibodySemantic proximity Read

Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapySemantic proximity Read

Aplastic Anemia Secondary to Dual Cancer Immunotherapies A Physician Nightmare: Case Report and Literature ReviewSemantic proximity Read

Teclistamab: Mechanism of action, clinical, and translational scienceSemantic proximity Read

Treatment outcome of newly diagnosed multiple myeloma patients: A retrospective analysis in a resource-limited settingSemantic proximity Read

Robust CD4 <sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelSemantic proximity Read

Patient Preferences for Treatment‑Free Intervals in Multiple Myeloma: Mixed‑Methods Insights on Monitoring Trade‑offs and Supportive Care ImprovementsSemantic proximity Read

Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 daysSemantic proximity Read

Cytokine Release Syndrome–Compatible Fever After Initiation of Local Radiotherapy During Late-Phase Epcoritamab Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case ReportSemantic proximity Read